Skip Navigation

European Heart Journal 1996 17(Supplement B):21-23; doi:10.1093/eurheartj/17.suppl_B.21
Copyright © 1996 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Packer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Packer, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 1996 The European Society of Cardiology

Beta-blockade in the management of chronic heart failure

Another step in the conceptual evolution of a neurohormonal model of the disease

M. Packer

Division of Circulatory Physiology and Center for Heart Failure Research, Columbia University College of Physicians and Surgeons, New York, NY, U.S.A.

Correspondence: Milton Packer, MD, Division of Circulatory Physiology, Columbia-Presbyterian Medical Center, 630 West 168th Street, New York, NY 10032, U.S.A.

Although heart failure has been viewed primarily as a haemodynamic disorder, the development of pharmacologic agents that address the haemodynamic derangements has not proved to be a successful approach to its management. Consequently, attention in recent years has shifted to the development of neurohormonal antagonists in the hope that prolonged interference with the renin-angiotensin system and the sympathetic nervous system would have favourable effects on the natural history of heart failure. Both converting-enzyme inhibitors and beta-adrenergic blockers have been shown to produce long-term haemo dynamic and clinical benefits in patients with left ventricular systolic dysfunction in controlled clinical trials. For both classes of drugs, the improvement evolves gradually over several months, although initiation of therapy may be accompanied by undesirable (but usually transient) haernodynamic effects. This pattern of response contrasts sharply with the response pattern seen with direct-acting vasodilators that stimulate neurohormonal systems (e.g. flosequinan). Initiation of treatment with fiosequinan produces inimediate clinical benefits due to the haemodynamic actions of the drug, but this improvement may disappear within weeks as a result of neurohormonal activation, which also may contribute to the increased risk of death seen during long-term administration of the drug. Recognition of the prognostic importapce of neurohormonal activation has led to the hope that long-term treatment with beta-blockers might reduce mortality in heart failure, in a manner similar to that seen with converting-enzyme inhibitors. Large-scale, long-term studies are being planned to evaluate this possibility.

Key Words: Heart failure • neurohormones • beta-blockers • clinical trials


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.